Матриксные металлопротеиназы при заболеваниях поджелудочной железы

1. Nagase H, Woessner JF. Matrix Metalloproteinases. J Biol Chem 1999; 274 (31): 21491–4.
2. Клишо Е.В., Кондакова И.В., Чойнзонов Е. Л. и др. Прогностическая значимость протеаз у больных плоскоклеточными карциномами головы и шеи. Бюллетень СО РАМН. 2005; 2 (116): 82–91.
3. Troeberg L, Nagase H. Analysis of TIMP expression and activity. Methods Mol Med 2007; 135: 251–67.
4. Bode W, Fernandez-Catalan С, Tschesche H et al. Structural properties of matrix metalloproteinases. Cell Mol Life Sci 1999; 55: 639–52.
5. Lehrke M, Greif M, Broedl UC et al. MMP-1 serum levels predict coronary atherosclerosis in humans. Cardiovasc Diabetol 2009; 8: 50.
6. Jefferis BJ, Whincup P, Welsh P et al. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis 2009; 19.
7. Соловьева Н.И. Матриксные металлопротеиназы: регуляция активности и роль в процессе онкогенеза. Вопр. мед. химии. 2000; 5: 30–1.
8. Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 2006; 11: 1696–701.
9. Porter S, Clark IM, Kevorkian L, Edwards DR. The ADAMTS metalloproteinases. Biochem J 2005; 386 (Pt 1): 15–27.
10. Kazushi I, YasuoY, Isao N et al. Matrix metalloproteinase 7 (Matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J Biol Chem 1995; 270 (12): 6691–7.
11. D'Alessio S, Ferrari G, Cinnante K et al. Tissue inhibitor of metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism. J Biol Chem 2008; 283 (1): 87–99.
12. Woessner JFJr. MMPs and TIMPs – an historical perspective. Mol Biotechnol 2002; 22 (1): 33–49.
13. Hilska M, Roberts PJ, Collan YU et al. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 2007; 121 (4): 714–23.
14. Giannopoulos G, Pavlakis K, Parasi A et al. The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. Anticancer Res 2008; 28 (3B):
1875–81.
15. Melendez-Zajgla J, Del Pozo L, Ceballos G, Maldonado V. Tissue inhibitor of metalloproteinases-4. The road less traveled. Mol Cancer 2008; 7: 85.
16. Zhang BB, Cai WM, Weng HL et al. Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis. World J Gastroenterol 2003; 9 (11): 2490–6.
17. Di Carlo C, Bonifacio M, Tommaselli GA et al. Metalloproteinases, vascular endothelial growth factor, and angiopoietin 1 and 2 in eutopic and ectopic endometrium. Fertil Steril 2009; 91 (6): 2315–23.
18. Gabison EE, Hoang-Xuan T, Mauviel A et al. EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie 2005; 87 (3–4): 361–8.
19. Bister V, Skoog T, Virolainen S et al. Increased expression of matrix metalloproteinases-21 and -26 and TIMP-4 in pancreatic adenocarcinoma. Mod Pathol 2007; 20 (11): 1128–40.
20. Varga F, Rumpler M, Spitzer S et al. Osteocalcin attenuates T3and increases vitamin D3-induced expression of MMP-13 in mouse osteoblasts. Endocr J 2009; 56 (3):
441–50.
21. Sochor M, Richter S, Schmidt A еt al. Inhibition of matrix metalloproteinase-9 with doxycycline reduces pancreatitisassociated lung injury. Digestion 2009; 80 (2): 65–73.
22. Фефилова И. Дермагенетика – новые возможности для эстетической медицины. Les Nouvelles Esthetiques 2008; 1.
23. Ali HA, Berkovitz R, Reich R, Srebnik M. Matrix metalloproteinase (MMP-2) organoboronate inhibitors. Arch Pharm (Weinheim) 2004; 337 (4): 183–7.
24. Guo K, Ma Q, Wang L еt al. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep 2009; 22 (4): 825–30.
25. Беловол А.Н., Князькова И.И. Клиническая эффективность медленнодействующих препаратов у больных с деформирующим остеоартрозом. Здоров'я Украины. 2008; 11 (1): 89–92.
26. Botos I, Scapozza L, Zhang D et al. Batimastat, a potent matrix metalloproteinase inhibitor, exhibits an unexpected mode of binding. Proc Nat Acad Sci USA 1996; 93 (7):
2749–54.
27. Bramhall SR. The matrix metalloproteinases and their inhibitors in pancreatic cancer. Int J Pancreatol 1997; 21 (1): 1–12.
28. Григорьева И.Н. Наследственные панкреатиты. Клин. перспект. гастроэнтерол., гепатол. 2007; 6: 27–30.
29. Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U at al. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 2009; 38 (6): 613–8.
30. Zhang Y, Chen C, Yao Q Li M. ZIP4 upregulates the expression   of   neuropilin-1,   vascular   endothelial growth factor, and matrix metalloproteases in pancreatic cancer cell lines and xenografts. Cancer Biol Ther 2010; 9 (3).
31. Tian M, Cui YZ, Song GH et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008; 8: 241.
32. Yamamoto H, Itoh F, Iku S et al. Expression of matrix metalloproteinase in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 2001; 19 (4): 1118–27.